Latest Articles
If it’s your first time on this website, please read the disclaimer section.
Jul 20 – Jul 27, 2026
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This International Myeloma Working Group recommendation provides updated guidelines for the diagnosis, evaluation, treatment, and response assessment of solitary plasmacytomas (SPs), rare localized tumors of clonal plasma cells. It highlights that approximately 50% of SPs progress to symptomatic myeloma within 5 years, necessitating careful exclusion of multiple myeloma using advanced diagnostics. Local radiotherapy is the mainstay therapy, with systemic therapy’s benefit remaining poorly defined. These recommendations offer crucial guidance for clinicians managing this cancer, emphasizing accurate diagnosis and follow-up given the significant progression risk.
10.1200/JCO-26-00410
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This phase 3 trial compared perioperative enfortumab vedotin-pembrolizumab (EV-P) versus neoadjuvant cisplatin-gemcitabine in 808 cisplatin-eligible muscle-invasive bladder cancer patients. At 33.6 months median follow-up, 2-year event-free survival was 79.4% with EV-P versus 66.2% with chemotherapy (HR 0.53; p<0.001), and overall survival was 86.9% versus 81.3% (HR 0.65; p=0.006). Pathological complete response rates were 55.8% versus 32.5% (p<0.001), though grade ≥3 adverse events were higher with EV-P (75.7% vs 67.2%). For bladder cancer practice, EV-P offers a chemotherapy-free perioperative alternative with superior efficacy, though the toxicity profile requires consideration in shared decision-making.
10.1056/NEJMoa2601486
Jul 13 – Jul 20, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 2 trial evaluated the safety and efficacy of teclistamab-based induction regimens (Tec-DR or Tec-DVR) in 49 transplant-eligible patients with newly diagnosed multiple myeloma. Results demonstrated a 100% overall response rate and a 91.8% MRD-negative complete response rate by the premaintenance timepoint, with 100% MRD negativity achieved in all evaluable samples at cycle 6. While grade 3/4 adverse events occurred in 91.8% of patients—primarily hematologic toxicities—cytokine release syndrome was limited to grade 1 or 2 (67.3%) and no neurotoxicity was reported. These findings suggest that teclistamab-based induction is a highly effective and feasible strategy for achieving deep molecular responses in frontline myeloma treatment before stem cell transplantation.
10.1038/s41591-026-04471-x
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 1 trial evaluated the safety and feasibility of autologous, trivalent T cells targeting WT1, PRAME, and survivin in pediatric patients with central nervous system tumors. Researchers determined the maximum tolerated dose at 8 x 10^7 cells/m^2, noting that treatment was generally well-tolerated despite one grade 5 dose-limiting toxicity involving tumor edema. Clinical results showed a median overall survival of 13.7 months for diffuse intrinsic pontine glioma and a median progression-free survival of 5.0 months for relapsed malignancies. These findings demonstrate the feasibility of multi-antigen-targeting T cells and provide preliminary signals of efficacy, including one complete response and long-term survival in select patients.
10.1038/s41591-026-04449-9
Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This ASCO guideline update utilized a systematic review and Delphi consensus to establish recommendations for breast cancer surveillance following primary treatment. The panel identified one randomized controlled trial supporting mammography, while other recommendations rely on expert consensus due to a lack of high-quality comparative data for risk-based approaches. Key findings advocate for regular history, physical examinations, and mammography, with the option for virtual visits and intensified monitoring for high-risk patients with locally advanced or residual disease. These guidelines provide a standardized, risk-based framework for clinicians to manage long-term follow-up and optimize detection of recurrence in breast cancer survivors.
10.1200/JCO-26-01700
A Multimodal Deep Learning Model for Preoperative Prediction of Postoperative Complications in Gastric Cancer.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This multicenter study developed and validated DeepComp, a multimodal deep learning model, to preoperatively predict postoperative complications (CD grade ≥II) and long-term survival in 5,237 gastric adenocarcinoma patients, integrating clinical and imaging data. DeepComp achieved an AUC of 0.888 (internal validation) and 0.824-0.869 (external cohorts), outperforming clinical baselines by 15.3 percentage points, and improved surgeon sensitivity from 47.1% to 87.9%. The model independently predicted overall survival (HR 3.08) and demonstrated significant absolute risk reductions for complications (e.g., 20.6% with nutritional support) through guided interventions, directly impacting cancer patient outcomes. DeepComp offers robust preoperative risk stratification, supporting individualized perioperative management to potentially reduce complications and improve long-term survival for gastric cancer patients.
10.1016/j.annonc.2026.07.004
Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non-Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART).
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
The DART study investigated concurrent and consolidative durvalumab with definitive radiation therapy for cCRT-ineligible patients with inoperable, locally advanced non-small cell lung cancer (LA-NSCLC) in a multicenter, single-arm, prospective phase II trial. The study met its primary endpoint, demonstrating a 2-year progression-free survival of 39% compared to historical 20%, with a 2-year overall survival of 54%. Grade 3/4 treatment-related adverse events occurred in 21% of patients. This offers a promising new treatment option for a vulnerable LA-NSCLC patient population lacking a standard of care, directly impacting oncology practice.
10.1200/JCO-25-02517
Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study aimed to develop and externally validate a transcriptome-based multivariable model predicting treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients after tyrosine kinase inhibitor (TKI) discontinuation. Researchers profiled peripheral blood transcriptomes from 96 CML patients to identify a 50-gene signature, which was then validated in an independent cohort of 70 patients. The signature effectively discriminated patients achieving sustained 2-year TFR from those relapsing, showing an AUROC of 0.83 in the training cohort and 0.71 in the external validation cohort. This predictive model offers a robust biomarker to guide TKI discontinuation decisions, potentially improving CML patient management and quality of life by identifying candidates for successful treatment cessation.
10.1200/JCO-25-02948
Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This multicenter, randomized phase III trial (NRG Oncology/RTOG 0848, Step 2) investigated whether adding fluoropyrimidine sensitized radiotherapy (CXRT) to adjuvant chemotherapy improves overall survival (OS) after curative resection for pancreatic head adenocarcinoma. Overall, adjuvant CXRT did not significantly improve OS (HR 0.96 [90% CI, 0.79 to 1.18], p=.77) or DFS, but increased grade 3 toxicity (38% vs 19%, p<.001). Significantly, CXRT improved OS (p=.0063) and DFS (p=.014) in node-negative patients. These findings suggest a potential benefit of adjuvant CXRT for node-negative pancreatic cancer patients, warranting further investigation with current systemic therapies.
10.1200/JCO-25-02520
Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This population-based screening study and randomized trial in Iceland (n=75,422) investigated the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM). Screening led to a 27-fold increase in smoldering MM detection (8.6% vs 0.3%; HR 27.46) and diagnosed active MM and related malignancies 1 year earlier in intervention arms, with fewer symptomatic presentations. Importantly, MGUS notification was not associated with adverse psychological outcomes, demonstrating earlier cancer detection without psychological harm. These findings suggest population-based screening facilitates earlier MM diagnosis and access to early intervention, though long-term survival and cost-effectiveness require further investigation.
10.1200/JCO-25-02771
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
The phase Ia/b TRAVERSE trial investigated ALLO-316, an allogeneic CD70-targeted CAR T-cell therapy, for advanced clear cell renal cell carcinoma (ccRCC) refractory to prior treatments, using a modified 3+3 design. With a median follow-up of 28.8 months, ALLO-316 showed manageable safety, with grade ≥3 neutropenia in 62.0% of patients. Encouraging antitumor activity was observed, with an objective response rate of 17.4% overall, increasing to 31.3% in phase Ib patients with CD70 tumor proportion score ≥50%. This study offers a novel therapeutic approach for advanced ccRCC, demonstrating proof of concept for allogeneic CAR T-cell therapy in solid tumors, which is highly relevant for cancer treatment.
10.1200/JCO-26-00388
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This secondary analysis of the TRIANGLE trial evaluated the efficacy and safety of adding rituximab maintenance (RM) to ibrutinib-containing regimens for younger, treatment-naïve patients with mantle cell lymphoma. Results demonstrated that RM significantly improved 4-year progression-free survival (PFS) in both the ibrutinib-only arm (85% vs 73%, p=.003) and the ibrutinib plus autologous stem-cell transplantation arm (90% vs 75%, p<.001). While RM showed a trend toward improved overall survival, it was associated with a higher risk of grade 3 to 5 infectious toxicities, reaching up to 41% in the transplant group. These findings support incorporating RM into BTK inhibitor-based protocols to achieve prolonged remission in this specific oncological population, despite the increased risk of infection.
10.1200/JCO-26-00705
Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This phase 3, randomized, placebo-controlled trial evaluated dabrafenib plus trametinib in 153 adults with radioactive iodine-refractory BRAF-positive differentiated thyroid cancer. The combination significantly extended progression-free survival (median 12.8 months vs 3.7 months; HR 0.38, p<0.0001) and improved overall response rate (57% vs 4%) compared to placebo. While overall survival did not reach significance in interim analysis, the safety profile showed no new signals. These findings support the second-line use of dabrafenib plus trametinib, offering a new therapeutic option for this challenging cancer population.
10.1016/S1470-2045(26)00133-6
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This ASCO Living Guideline provides evidence-based recommendations for systemic treatment of recurrent high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. Based on a systematic review of 147 RCTs and systematic reviews, key findings include strong recommendations for platinum-based combination regimens (PLD plus carboplatin, paclitaxel plus carboplatin, gemcitabine plus carboplatin) in platinum-sensitive disease, with bevacizumab as an optional addition. For platinum-resistant disease with FRα expression, mirvetuximab soravtansine is strongly recommended, alongside options like PLD monotherapy, weekly paclitaxel, or relacorilant plus nab-paclitaxel. These recommendations directly support clinicians in selecting systemic therapies for recurrent ovarian cancer, a primary cancer focus, with clear numerical evidence from the included trials.
10.1200/JCO-26-01591
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This double-blind, randomized phase 3 trial used prospective ctDNA monitoring to detect ESR1 mutations before clinical progression in HR+/HER2- advanced breast cancer patients on first-line aromatase inhibitor plus CDK4/6 inhibitor. Switching to camizestrant plus CDK4/6 inhibitor at mutation emergence significantly improved median progression-free survival (16.8 vs 9.2 months; HR 0.45) and second progression-free survival (25.7 vs 19.1 months; HR 0.63). The strategy aligns directly with cancer-focused interests by addressing acquired endocrine resistance through targeted therapy switch guided by ctDNA. Clinically, this supports preemptive ESR1 mutation surveillance and immediate endocrine therapy change to camizestrant to extend first-line benefit while continuing CDK4/6 inhibition.
10.1016/S1470-2045(26)00287-1
Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This review examines the evolving management of HER2-positive breast cancer, focusing on the impact of successive generations of targeted therapies including monoclonal antibodies and antibody-drug conjugates. Advances have extended median survival from under two years to common long-term survival beyond five years, with trastuzumab deruxtecan (T-DXd) showing unprecedented efficacy in both metastatic and curative settings. The shift toward earlier T-DXd use necessitates new strategies for treatment sequencing and the management of specific toxicities, such as interstitial lung disease. Clinicians must adapt to a landscape where de novo metastatic presentations are increasing, requiring a nuanced approach to downstream therapy selection and patient monitoring.
10.1200/JCO-26-00672
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase III randomized trial (ENHANCE) evaluated the efficacy and safety of adding magrolimab, a CD47-targeted antibody, to azacitidine in 539 treatment-naïve patients with higher-risk myelodysplastic syndromes. Results showed no significant improvement in complete remission rates (21.3% vs. 23.6%) or median overall survival (15.9 vs. 18.6 months) compared to placebo plus azacitidine. Furthermore, the magrolimab group experienced higher rates of grade ≥3 adverse events (92.8% vs. 79.2%) and fatal toxicities (15.2% vs. 9.8%). These findings demonstrate that magrolimab does not provide clinical benefit in this cancer population and carries a higher risk of severe toxicity, discouraging its use in untreated higher-risk MDS.
10.1200/JCO-25-00617
Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This randomized controlled trial compared virtual sustained tobacco treatment (VST) to enhanced usual care (EUC) for smoking cessation in 306 recently diagnosed cancer patients across 37 community oncology sites. At six months, VST significantly improved 7-day point abstinence rates (28.4% vs. 14.7% for EUC) and continuous abstinence, with VST participants almost four times more likely to use guideline-concordant medication. This study offers a highly relevant, effective, and scalable intervention to improve smoking cessation among cancer patients, directly impacting their clinical outcomes. The findings strongly support integrating sustained, remotely delivered tobacco treatment, including telehealth and free NRT, into routine community oncology care.
10.1200/JCO-25-02267
YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This randomized noninferiority trial (n=698) compared the YEARS algorithm to CTPA-only for diagnosing suspected pulmonary embolism (PE) in patients with active cancer. The YEARS algorithm was noninferior to CTPA-only regarding the 90-day risk of venous thromboembolism or PE-related death (1.8% vs 5.5%; absolute risk difference -3.7%, P=3.4x10^-5). Crucially, the YEARS algorithm obviated the need for CTPA in 22% of patients. These findings indicate that the YEARS algorithm is a safe and efficient diagnostic strategy for PE in cancer patients, offering a valuable approach to reduce radiation exposure and optimize care in this vulnerable population.
10.1001/jama.2026.10676
Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This phase 3 randomized trial (JCOG1403) evaluated the efficacy of a single intravesical instillation of pirarubicin versus observation in preventing bladder recurrence for 304 patients following radical nephroureterectomy for upper tract urothelial carcinoma. Results demonstrated a significant improvement in 3-year relapse-free survival, which was 60.0% in the pirarubicin group compared to 47.0% in the observation group (HR 0.67; p=0.0066). The intervention directly addresses the high risk of metachronous bladder cancer, showing manageable toxicity with only 3% of patients experiencing grade 3-4 hematuria. These findings establish early postoperative pirarubicin instillation as an effective evidence-based strategy to reduce oncological recurrence in this patient population.
10.1016/S1470-2045(26)00130-0
Jul 06 – Jul 13, 2026
CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This review examines the translational progress of CRISPR-Cas technologies in clinical oncology, focusing on their role in molecular diagnostics and therapeutic interventions. The authors highlight how CRISPR-enabled functional genomics identify novel cancer dependencies and resistance mechanisms, while emerging diagnostic tools offer rapid mutation detection. Therapeutic applications discussed include ex vivo immune cell engineering and in vivo targeting of specific tumor sequences like fusion junctions or single-nucleotide variants. Despite challenges in delivery and regulation, these technologies represent a modular platform for addressing undruggable oncogenic drivers and improving durable clinical benefits in cancer care.
10.1038/s41571-026-01179-2
Global Consensus on the Management of Primary Localized Chordoma.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This global consensus statement updated multidisciplinary recommendations for managing primary, localized chordoma, a rare malignant bone tumor with 40-60% metastatic spread. Developed by experts and patient representatives through a comprehensive literature review (305 articles), it emphasizes treatment at experienced centers with maximally safe surgery followed by high-dose radiotherapy. Guidance covers diagnosis, surgical approaches, radiotherapy planning, systemic therapy, and long-term follow-up across anatomical sites. This aims to harmonize clinical practice and support shared decision-making for this challenging cancer.
10.1001/jamaoncol.2026.2054
Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This post hoc analysis of the phase 3 TOPAZ-1 trial evaluated the 4-year overall survival (OS) and safety of durvalumab plus gemcitabine and cisplatin (GemCis) as a first-line treatment for advanced biliary tract cancer (aBTC). Among 685 randomized participants, median OS was 13.0 months for durvalumab plus GemCis versus 11.4 months for placebo plus GemCis (HR, 0.75), with a 48-month OS rate of 11.8% vs 4.3%, respectively. The study demonstrates a long-term survival benefit for a specific cancer type, directly aligning with the clinician’s interest in cancer research. These findings reinforce durvalumab plus GemCis as a first-line standard of care for aBTC, offering improved patient outcomes with a manageable safety profile.
10.1001/jamaoncol.2026.2204
Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320).
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This phase 2 randomized clinical trial investigated consolidative thoracic radiotherapy (TRT) combined with atezolizumab maintenance versus atezolizumab alone in 68 patients with extensive-stage small cell lung cancer (ES-SCLC) after induction chemoimmunotherapy. The study found that TRT plus atezolizumab resulted in numerically shorter median overall survival (6.7 months vs 13.4 months; HR, 1.55) and similar median progression-free survival (2.4 months vs 2.6 months). Importantly, the combination arm showed significantly higher severe adverse events (61.3% vs 18.2%; P < .001) and fatal outcomes (19.4% vs 3.0%; P = .04). These findings suggest that adding consolidative TRT to immunotherapy maintenance in unselected ES-SCLC patients increases toxicity without survival benefit, highlighting the need for cautious patient selection.
10.1001/jamaoncol.2026.2330
Global breast cancer survival estimates in 2017-2021 to advance the WHO Global Breast Cancer Initiative.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This WHO study estimated population-based 5-year net survival for women diagnosed with breast cancer between 2017 and 2021 across 194 Member States. Results revealed stark regional disparities, with median survival ranging from 39.1% in the African Region to 88.5% in the Region of the Americas. These findings directly address the clinician’s interest in cancer by providing a global benchmark for monitoring outcomes and identifying critical gaps in care. The data underscores the urgent need for sustained initiatives to improve access to diagnosis and treatment to achieve global mortality reduction targets.
10.1038/s41591-026-04531-2
Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This phase 3 randomized controlled trial (PERISCOPE II) investigated gastrectomy with cytoreductive surgery and HIPEC versus systemic therapy alone for gastric cancer with limited peritoneal metastases. In 102 participants, median overall survival was 16.6 months (systemic therapy) versus 15.7 months (experimental group), demonstrating no survival benefit (HR 1.10; p=0.70). The experimental group experienced higher rates of grade 3+ adverse events (42% vs 20%) and three treatment-related deaths. These findings indicate that gastrectomy with cytoreductive surgery and HIPEC offers no survival advantage over systemic therapy alone for this cancer population and is associated with increased morbidity.
10.1016/S1470-2045(26)00144-0
Lung Transplant for Refractory Lung-Limited Stage IV Non-Small Cell Lung Cancer.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This prospective, single-center registry study investigated the overall survival of 17 selected patients with medically refractory, lung-limited, stage IV non-small cell lung cancer (NSCLC) who underwent lung transplant compared to 81 similar patients receiving medical management alone. The 1-year overall survival was significantly higher for transplant recipients (100.0%) versus medical management (40.8%), an absolute difference of 59.2 percentage points. This research directly addresses a critical cancer-related question, demonstrating favorable early survival outcomes for a previously untreatable advanced NSCLC population. Lung transplant may offer a viable, life-extending option for carefully selected patients with refractory, lung-limited stage IV NSCLC, challenging historical treatment paradigms.
10.1001/jama.2026.8717
Intracranial Injection of Investigational Ex Vivo Expanded and Activated Gamma-Delta T Cells Engineered With a Methylguanine-DNA Methyltransferase-Expressing Lentivector in Patients With Primary Glioblastoma.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study investigated a novel approach for newly diagnosed glioblastoma (GBM) using genetically modified, temozolomide (TMZ)-resistant gamma-delta (γδ) T cells (DeltEx DRI) delivered intracranially via a Rickham catheter, combined with TMZ. In 13 treated patients, no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity were observed. The median progression-free survival (mPFS) was 9.9 months for all patients (16.1 months for repeated doses), and median overall survival (mOS) was 15.6 months. This investigational immunotherapy shows promising safety and early efficacy signals for a challenging cancer, glioblastoma, suggesting a potential new, well-tolerated treatment strategy warranting further investigation.
10.1200/JCO-25-02463
Advances in systemic therapies for advanced prostate cancer.
BMJ-BRIT MED J · Q1 JOURNAL - RANK #5/332TOP-TIER
This review summarizes the latest progress in managing advanced prostate cancer, including high-risk biochemical recurrence, metastatic hormone-sensitive prostate cancer (mHSPC), and metastatic castration-resistant prostate cancer (mCRPC), by synthesizing landmark clinical trials and meta-analyses. Key findings indicate improved patient outcomes with earlier use of androgen receptor pathway inhibitors in high-risk biochemical recurrence and mHSPC. Advanced imaging and genomic biomarkers enhance patient selection for personalized therapy, while chemotherapy, PARP inhibitors, and Lu-PSMA-617 have refined treatment roles. The review directly addresses advancements in systemic therapies for a specific cancer type, prostate cancer, highlighting personalized therapy, biomarker-guided treatment, and adverse event management for clinical practice.
10.1136/bmj-2025-085211
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This Phase III randomized trial (POLARGO) evaluated the efficacy and safety of adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) in 255 transplant-ineligible patients with relapsed or refractory diffuse large B-cell lymphoma. Results demonstrated a significant improvement in overall survival for the Pola-R-GemOx group compared to R-GemOx alone, with a median survival of 19.5 months versus 12.5 months (HR 0.6; p = .0017). While efficacy was superior, the Pola-R-GemOx arm showed higher rates of peripheral neuropathy (57% vs. 29%) and fatal adverse events (12% vs. 4%), primarily driven by infections. These findings establish Pola-R-GemOx as a viable and effective treatment option for this high-risk cancer population, provided clinicians carefully manage the increased risk of toxicity.
10.1200/JCO-25-02849
Jun 29 – Jul 06, 2026
Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This study reports the development of the SSTR-PeRForm framework for neuroendocrine tumor (NET) response assessment using a modified Delphi process involving 34 international experts. The consensus defines partial response as a ≥40% reduction in target lesion volume and progressive disease as a ≥40% volume increase or the appearance of new lesions. By prioritizing volumetric changes over standardized uptake value (SUV) metrics, the framework offers a standardized approach for evaluating therapy efficacy in cancer patients. While pending survival outcome validation, this pragmatic foundation harmonizes PET-based assessment for clinical trials and routine oncological practice.
10.1016/S1470-2045(26)00145-2
Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This prospective analysis of 298 patients from the CIRCULATE-Japan GALAXY study evaluated whether postsurgical ctDNA-defined molecular residual disease (MRD) predicts survival and adjuvant chemotherapy (ACT) benefit in resected colorectal liver metastases. In the upfront surgery cohort, MRD-positive patients receiving ACT showed significantly improved survival (OS HR 0.27; 48-month OS 65.3% vs 32.9%), whereas MRD-negative patients derived no benefit (OS HR 0.54, P=.47). For the neoadjuvant chemotherapy cohort, MRD positivity remained a strong prognostic indicator for worse outcomes (OS HR 9.43), though ACT did not significantly improve survival regardless of MRD status. These findings suggest that ctDNA status can effectively guide personalized adjuvant treatment strategies, potentially sparing MRD-negative patients from unnecessary chemotherapy while identifying those who require intensive intervention.
10.1001/jamaoncol.2026.2191
Generalizable AI predicts immunotherapy outcomes across cancers and treatments.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This study introduces COMPASS, a pan-cancer foundation model using a concept bottleneck transformer to predict immunotherapy response from bulk tumor transcriptomes across 33 cancer types. COMPASS outperformed 22 existing methods across 16 clinical cohorts, improving predictive accuracy by 8.5% and demonstrating a significant survival benefit for predicted responders (HR = 4.7, P < 0.0001). The model generalizes across diverse cancer types and treatments, offering a robust tool for patient stratification and identifying specific biological programs associated with treatment resistance. These findings suggest that biologically grounded AI can enhance clinical trial design and personalized oncology by providing mechanistic insights into immune-mediated response and exclusion.
10.1038/s41591-026-04502-7
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This post-hoc analysis of the PACIFIC trial investigated the impact of baseline proton pump inhibitors (PPIs) and antibiotics on durvalumab efficacy in 660 patients with unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy. In the durvalumab group, PPI exposure significantly shortened progression-free survival (9.4 vs 17.2 months; HR 1.57; p<0.0001) and overall survival (33.0 vs 57.9 months; HR 1.66; p<0.0001). Antibiotic exposure also reduced progression-free survival (9.2 vs 15.6 months; HR 1.50; p=0.016) but not overall survival. These findings suggest that baseline PPI and antibiotic use may attenuate the benefit of durvalumab in NSCLC, highlighting a critical consideration for clinical practice.
10.1016/S1470-2045(26)00191-9
A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.
NAT REV CANCER · Q1 JOURNAL - RANK #3/326TOP-TIER
This review examines recent advances in genomic and epigenomic profiling of acute lymphoblastic leukaemia (ALL) to identify molecular subtypes and genetic drivers. Research has identified over 40 molecular subtypes of B-cell precursor ALL defined by distinct transcriptional programs, while also uncovering biologically defined T-cell ALL subtypes. These genomic insights inform risk stratification and the use of targeted therapies for kinase-activating alterations, though clonal evolution and epigenetic reprogramming continue to drive treatment resistance. Integrating these molecular findings into clinical practice enhances diagnostic classification and therapeutic outcomes by addressing the genetic heterogeneity inherent in ALL progression.
10.1038/s41568-026-00951-x
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study developed and validated the PRISM prognostic model for risk stratification in 2,092 adults with newly diagnosed Acute Myeloid Leukemia (AML) treated with hypomethylating agents plus venetoclax (HMA + VEN), using a multinational dataset and robust statistical modeling. PRISM integrated 17 clinical and genomic variables, demonstrating a linear association with overall survival. Key findings showed PRISM-3 stratified survival consistently, with median OS ranging from 25.1-28.8 months for low risk to 5.8-6.7 months for high risk (p < .001), significantly outperforming the 4-gene classifier (C-index 0.63-0.65 vs 0.59-0.61; p < .05). This model directly enhances cancer prognosis for AML patients, supporting individualized, risk-adapted clinical decision-making and improving patient management in oncology.
10.1200/JCO-26-00347
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This randomized Phase III trial compared temozolomide versus standard radiotherapy as first-line therapy for 478 patients with clinical high-risk WHO grade 2 low-grade gliomas. Overall, there was no significant difference in progression-free or overall survival between treatment arms. However, in tumors without IDH mutations (n=64), overall survival significantly favored the temozolomide arm (4.7 vs 2.5 years; HR 0.47, p=0.0068). This study provides crucial insights into optimal first-line treatment strategies for low-grade gliomas, emphasizing the necessity of molecular classification for tailored cancer management and challenging the prognostic value of age alone.
10.1200/JCO-25-02735
Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This prospective, cross-sectional diagnostic study evaluated circulating methylated SEPT9 combined with α-Fetoprotein (AFP) for hepatocellular carcinoma (HCC) detection in 574 cirrhosis patients. Methylated SEPT9 alone outperformed AFP (AUROC: 0.79 vs 0.71, P=.002). Combining them (Tier 1a) achieved 87.8% sensitivity, recovering 78% of AFP-missed HCC cases. For early-stage HCC (BCLC 0-A), Tier 1a sensitivity was 74.5% versus 23.5% for AFP, a 3.2-fold increase. This combination substantially improves HCC detection, particularly for early-stage disease amenable to curative treatment.
10.1001/jamaoncol.2026.2157
Systemic health impact of cancer-associated extracellular vesicles and particles.
NAT REV CANCER · Q1 JOURNAL - RANK #3/326TOP-TIER
This review examines the role of cancer-associated extracellular vesicles and particles (EVPs) in mediating systemic effects and multi-organ dysfunction. The authors describe how EVPs facilitate intercellular communication to create pre-metastatic niches and drive complications including cachexia, thrombosis, and metabolic disorders. For the clinician, the study clarifies the mechanisms behind paraneoplastic syndromes and immune evasion that complicate primary cancer management. These findings suggest that targeting EVPs could serve as a holistic therapeutic approach to mitigate comorbidities and improve overall patient survival.
10.1038/s41568-026-00952-w
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This review summarizes current evidence and future directions for optimizing neoadjuvant and perioperative chemoimmunotherapy in early-stage, resectable non-oncogene-driven non-small-cell lung cancer (NSCLC). It highlights that this approach has become standard of care, demonstrating substantial increases in pathological response rates and improvements in overall survival, with pathological complete response (pCR) identified as a robust surrogate for durable benefit. The review explores integrating complementary tools like circulating tumor DNA, radiomics, and biomarkers to refine patient selection and dynamically adapt perioperative strategies. This aims to intensify treatment for high-risk populations, increase pCR likelihood, and improve disease control, offering critical implications for personalized NSCLC management.
10.1038/s41571-026-01174-7
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This open-label phase 3 trial at 50 Chinese hospitals randomized 287 HER2-positive metastatic breast cancer patients to trastuzumab rezetecan or pyrotinib plus capecitabine after prior trastuzumab and taxane. At 15-month median follow-up, trastuzumab rezetecan significantly improved median progression-free survival (30.6 vs 8.3 months; HR 0.22, p<0.0001) with 12-month PFS rates of 84.7% versus 35.5%. The primary toxicity was hematologic (grade ≥3 neutropenia 54% vs 9%), with 3% interstitial lung disease and no treatment-related deaths. This directly addresses your interest in cancer research, demonstrating a highly effective new HER2-targeted therapy with a distinct safety profile, offering a potential new standard for metastatic breast cancer.
10.1016/S1470-2045(26)00193-2
Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This multicenter phase 2 trial (PICC-2) randomized 110 patients with dMMR/MSI-H locally advanced colorectal cancer to neoadjuvant toripalimab (anti-PD-1) plus celecoxib (COX-2 inhibitor) or toripalimab alone. The combination achieved a significantly higher pathological complete response rate of 89% (49/55) versus 69% (38/55) with monotherapy (absolute difference 19%, p=0.014). Grade 3 adverse events were low in both arms (5% vs 7%), with no grade 4-5 events. For clinicians managing dMMR/MSI-H colorectal cancer, this combination neoadjuvant strategy markedly improves pCR without compromising safety, though phase 3 confirmation is needed.
10.1016/S1470-2045(26)00220-2
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase I/II study evaluated sonrotoclax monotherapy in 125 heavily pretreated patients with relapsed/refractory mantle cell lymphoma (MCL). The overall response rate by independent review committee (ORR-IRC) was 52.4% (p < .0001 vs. historic control), with a 15.5% complete response rate. Responses were durable, with a median duration of response of 15.8 months, and the drug demonstrated a manageable safety profile. These findings suggest sonrotoclax offers rapid, durable responses in a high-risk, pretreated MCL population, supporting its potential as a new oral therapeutic option for patients with relapsed/refractory MCL.
10.1200/JCO-26-00550
Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This comprehensive review evaluates the potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as metabolic modulators in cancer prevention and treatment. Epidemiologic evidence indicates GLP-1RA therapy correlates with a reduced risk of obesity-related malignancies, including gastrointestinal, breast, and endometrial cancers, through mechanisms like insulin signaling inhibition and immune modulation. The study highlights the utility of these agents in neoadjuvant settings to optimize metabolic health before surgery and as complementary therapies to overcome treatment resistance. GLP-1RAs represent a promising novel class of agents that bridge metabolic management and oncology, potentially improving outcomes for patients with obesity-driven cancers.
10.1200/JCO-26-00062
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This open-label, phase 3 trial enrolled 174 patients with stage III, HER2-negative, HRD breast cancer to compare intensified alkylating chemotherapy with autologous stem cell rescue (IACT) against conventional chemotherapy followed by olaparib. At 41 months median follow-up, 4-year overall survival was nearly identical: 77.0% for IACT versus 76.4% for olaparib-based therapy (HR 1.11, p=0.37). The olaparib regimen showed significantly fewer severe toxicities, including lower rates of grade 3-4 thrombocytopenia (19% vs 99%), neutropenia (61% vs 95%), and serious adverse events (26% vs 47%). For clinicians treating high-risk breast cancer with HRD, these results indicate that state-of-the-art chemotherapy plus olaparib achieves equivalent survival with substantially better tolerability than intensified chemotherapy with stem cell rescue.
10.1016/S1470-2045(26)00131-2
Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This phase 3 randomized trial (CAIRO6) compared perioperative systemic therapy plus cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) against upfront CRS-HIPEC alone in 358 patients with resectable colorectal peritoneal-only metastases. After a 41-month median follow-up, median overall survival was 44 months in the perioperative group versus 39 months in the surgery-alone group (HR 0.85, p=0.28), showing no statistically significant benefit. Major 90-day postoperative morbidity was higher in the perioperative group (36%) compared to the surgery-alone group (26%), with significant systemic therapy-related toxicities reported in 57% of patients. These findings suggest that perioperative systemic therapy should not be routinely recommended for all patients with resectable colorectal peritoneal metastases, favoring upfront surgery in this population.
10.1016/S1470-2045(26)00085-9
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
The ARTO trial, a multicentre, randomised phase 2 study, investigated the long-term impact of adding stereotactic body radiotherapy (SBRT) to abiraterone acetate and ADT in 157 patients with oligometastatic castrate-resistant prostate cancer. After a median follow-up of 53 months, the experimental group (SBRT + systemic therapy) showed significantly improved overall survival compared to systemic therapy alone (HR 0.55, 95% CI 0.33-0.92, p=0.021), with median OS of 50 months in the control group versus not reached in the experimental group. This indicates a substantial survival benefit by incorporating metastasis-directed therapy. The findings suggest that adding SBRT to standard systemic therapy is a clinically relevant strategy for improving outcomes in this specific prostate cancer population.
10.1016/S1470-2045(26)00178-6
European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This systematic review and joint statement by European consortia aimed to standardize imaging protocols for diagnosing, staging, and monitoring osteosarcoma and Ewing sarcoma. Analysis of 13 high-quality studies out of 2,026 identified significant heterogeneity in imaging practices, resulting in 32 consensus-based clinical recommendations. The guideline addresses critical gaps in detecting bone metastases and evaluating treatment response, though evidence remains inconclusive for specific MRI parameters or metabolic indices. These recommendations provide a harmonized framework for clinical practice while highlighting the urgent need for prospective international studies to establish evidence-based imaging standards in bone cancer care.
10.1016/S1470-2045(26)00141-5
Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This international expert consensus statement provides pragmatic guidance for reirradiation in recurrent or second primary head and neck squamous cell carcinoma (HNSCC) within previously irradiated regions, a scenario with few therapeutic options. Developed through a structured expert consensus process, it reflects current expert practice across key domains including patient selection, imaging, and toxicity management. The consensus aims to promote more consistent practice and facilitate communication across centers for this complex cancer. It offers a shared clinical framework to support clinicians in making informed choices and guide future research efforts in HNSCC reirradiation.
10.1016/S1470-2045(26)00174-9
Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This review article advocates a paradigm shift for treating triple-negative breast cancer (TNBC) brain metastases by actively targeting and exploiting blood-brain barrier (BBB) biology. Synthesizing preclinical and clinical evidence, it delineates TNBC-specific BBB breach mechanisms and evaluates emerging therapies via a three-pillar framework: physical/focal BBB disruption, biological BBB exploitation, and microenvironmental modulation. The review provides a translational roadmap for unmet clinical needs in this aggressive cancer subtype. It emphasizes that integrated, BBB-centric strategies are crucial to improving patient outcomes, offering new avenues for clinical practice.
10.1016/S1470-2045(26)00146-4
Extranodal natural killer/T-cell lymphoma: From fatal to curable.
CA-CANCER J CLIN · Q1 JOURNAL - RANK #1/326TOP-TIER
This review examines the therapeutic evolution of extranodal natural killer/T-cell lymphoma (ENKTCL), an aggressive Epstein-Barr virus-associated malignancy prevalent in Asian and South American populations. Current standard care utilizing combined-modality therapies targeting genomic and metabolic vulnerabilities has shifted the prognosis, with nearly 80% of newly diagnosed patients now achieving long-term survival. The study highlights the transition from ineffective anthracycline-based regimens to precision approaches, including hematopoietic stem cell transplantation for high-risk cases and novel agents targeting oncogenic signaling. Future management focuses on overcoming relapsed/refractory disease through EBV-targeted cellular therapies and vaccines, aiming to transform this once-fatal cancer into a consistently curable condition.
10.3322/caac.70094
Imaging the hallmarks of cancer.
NAT REV CANCER · Q1 JOURNAL - RANK #3/326TOP-TIER
This review explores non-invasive diagnostic imaging capabilities for interrogating the hallmarks of cancer, a conceptual framework central to cancer research. It discusses approaches including direct targeting with imaging probes, indirect assessment of pathophysiological processes, and AI-assisted multiparametric image analysis. These technologies are crucial for monitoring treatment effectiveness, stratifying patients, and guiding various cancer therapies. Many discussed methods already play a substantial role in clinical practice, informing surgical resections, radiotherapy, and molecularly targeted chemo-, immuno-, and radiopharmaceutical treatments, thereby offering critical tools for personalized cancer management.
10.1038/s41568-026-00950-y
Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This multicentre, phase 3 randomized trial (INTRAGO-II) evaluated whether adding 30 Gy of intraoperative radiotherapy (IORT) to standard chemoradiotherapy improves outcomes in 298 patients with newly diagnosed glioblastoma. Results showed no significant difference in median progression-free survival between the IORT group (11.0 months) and the standard-of-care group (11.4 months; HR 1.1, p=0.47). Local recurrence remained the predominant failure pattern in both groups (~71%), while IORT was associated with higher rates of serious adverse events, including seizures (13% vs 7%) and radiation necrosis (7% vs 2%). These findings suggest that local dose intensification via IORT does not provide clinical benefit for resectable glioblastoma and should not be integrated into standard practice.
10.1016/S1470-2045(26)00235-4
Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This prospective registry study evaluated the 10-year outcomes of tailoring locoregional radiotherapy based on nodal response after primary chemotherapy in 838 patients with cT1-2N1 breast cancer. Results demonstrated a low overall 10-year locoregional recurrence rate of 2.9%, with specific rates of 2.4% in the low-risk group and 2.8% in the high-risk group. The study shows that de-escalating or omitting radiotherapy based on chemotherapy response does not significantly increase recurrence risk, maintaining a 10-year overall survival rate of 83.0%. These findings support a personalized approach to radiotherapy, potentially reducing treatment-related morbidity and improving quality of life for breast cancer survivors without compromising oncological safety.
10.1016/S1470-2045(26)00216-0
Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This unplanned subset analysis of the phase 3 EORTC 22922/10925 trial evaluated the 20-year impact of internal mammary and medial-supraclavicular (IM-MS) irradiation in 1,778 patients with pN0 stage I-III breast cancer. At 22.2 years median follow-up, IM-MS irradiation significantly reduced breast cancer mortality (10.0% vs 14.2%; HR 0.70) but did not improve overall survival (69.0% vs 68.4%; HR 0.98) due to increased non-breast cancer mortality (20.9% vs 17.4%). The findings highlight that while regional nodal irradiation provides long-term oncological control in node-negative patients with central/medial tumors, it carries risks of late toxicities like lung fibrosis (6.4% vs 2.1%). Clinicians must weigh the reduction in cancer-specific mortality against potential late-term treatment complications, emphasizing the need for modern radiation techniques to minimize collateral organ damage.
10.1016/S1470-2045(26)00233-0
Jun 22 – Jun 29, 2026
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
The JCOG1008 randomized phase II/III trial’s long-term follow-up compared weekly versus 3-weekly cisplatin chemoradiotherapy in 261 patients with postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). At 5.6 years median follow-up, 5-year overall survival was 58.7% (3-weekly) vs. 71.2% (weekly) (HR 0.76), confirming noninferiority of the weekly regimen. Weekly cisplatin also showed numerically better 5-year relapse-free and local RFS, with no significant late adverse event differences, directly impacting cancer treatment strategies. These results support weekly cisplatin plus radiotherapy as a reasonable and effective alternative for this specific cancer patient population.
10.1200/JCO-25-01708
First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This single-arm, phase II trial investigated first-line disitamab vedotin, tislelizumab, and S-1 for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma in 57 patients. The study reported a remarkable confirmed objective response rate of 89.5% (95% CI, 78.5 to 96.0), with a median progression-free survival of 13.8 months and median overall survival of 31.9 months. This novel combination therapy demonstrates significant antitumor activity and a manageable safety profile, directly addressing a critical need in cancer treatment. The promising results warrant validation in randomized controlled trials, potentially offering a new standard of care for this advanced cancer.
10.1200/JCO-26-00277
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This secondary analysis of the DAPHNe phase 2 trial assessed 5-year outcomes and ultrasensitive ctDNA dynamics in 98 patients with stage II-III ERBB2-positive breast cancer receiving neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP). With a median follow-up of 5.2 years, the 5-year event-free survival was 99% (95% CI, 97%-100%), and overall survival was 99% (95% CI, 97%-100%). Baseline ctDNA was detected in 89.5% of patients, with 96.1% achieving clearance post-neoadjuvant therapy. These findings demonstrate excellent long-term outcomes with neoadjuvant THP and support further investigation into ctDNA-guided de-escalation strategies for ERBB2-positive breast cancer.
10.1001/jamaoncol.2026.2023
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This study utilized targeted metabolomics and machine learning to analyze 4,336 plasma samples from 1,714 patients across five tumor types to identify metabolic predictors of immune-checkpoint inhibitor efficacy. Researchers identified five key metabolites, including histidine, long-chain fatty acids, and succinate, which predicted 12-month progression-free survival with validation AUCs of 0.73. Histidine was identified as a favorable prognostic marker, while histidine-rich diets significantly improved survival outcomes in patients lacking specific dysbiotic microbiome signatures. These findings suggest that plasma metabolic profiling and personalized nutritional interventions could optimize immunotherapy outcomes and patient stratification in clinical oncology.
10.1038/s41591-026-04481-9
Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study investigated genomic loss of mismatched HLA (HLA loss) as a mechanism of relapse in 533 patients with hematologic cancers after allogeneic hematopoietic cell transplantation (allo-HCT), utilizing a novel next-generation sequencing pipeline and a web-based HLA incompatibility phasing tool. HLA loss occurred in 15.6% of relapses, varying significantly by donor type (e.g., 28.7% haploidentical vs. 7.2% unrelated adult) and strongly associated with HLA mismatches on the same haplotype (27.6% vs. 5.4%). This loss abrogated original donor lymphocyte infusion efficacy but showed survival advantage with a second allo-HCT from a different donor. The findings support informed donor selection using the new phasing tool and warrant routine HLA loss assessment at relapse to guide salvage therapies for hematologic malignancies.
10.1200/JCO-26-00113
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This international, multicenter, retrospective cohort study investigated long-term outcomes and genotype-phenotype associations in 320 platinum-sensitive recurrent ovarian cancer patients with exceptional PARP inhibitor response (PFS ≥ 5 years). With a median follow-up of 6.8 years, 7.5-year and 10-year PFS rates were 88.8% and 78.7%, respectively, demonstrating sustained progression-free survival. Notably, patients discontinuing PARP inhibitors without progression achieved a 10-year PFS of 90.1% versus 72.5% for those continuing, with a low 1.6% risk of late-onset MDS/AML. These results provide crucial guidance for counseling on PARP inhibitor duration, suggesting functional cure is possible and informing decisions on treatment cessation in ovarian cancer.
10.1001/jamaoncol.2026.1924
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This randomized phase II trial evaluated whether adding pembrolizumab to sacituzumab govitecan (SG) improves outcomes in 104 patients with metastatic hormone receptor-positive/HER2-negative breast cancer. The combination did not significantly improve progression-free survival (8.4 vs 6.7 months; HR 0.76, p=0.12) or overall survival (20.0 vs 18.0 months) compared to SG monotherapy in the unselected population. However, a numerical trend favoring the combination was observed in PD-L1-positive patients, with median progression-free survival reaching 11.1 months versus 5.6 months (HR 0.51). While the primary endpoint was not met, these results suggest that immunotherapy combinations in breast cancer may require biomarker-driven selection, specifically PD-L1 expression, for future clinical application.
10.1016/j.annonc.2026.06.012
Jun 15 – Jun 22, 2026
Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity.
NAT REV CANCER · Q1 JOURNAL - RANK #3/326TOP-TIER
This review examines the shift from traditional viral oncogenesis to the emerging role of the human virome in enhancing antitumor immunity. It highlights how non-oncogenic viruses, endogenous retroviruses, and bacteriophages prime innate and adaptive immune responses, such as the enterovirus CE1 epitope’s protective role in liver cancer. The study explores mechanisms like immune checkpoint modulation and antigen mimicry, offering a framework for virome-guided cancer prevention and risk assessment. These insights suggest new avenues for immune-based therapeutics and cancer control strategies, particularly in low-resource settings.
10.1038/s41568-026-00948-6
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This phase 3, double-blind, placebo-controlled trial (frontMIND) evaluated tafasitamab plus lenalidomide with R-CHOP versus R-CHOP alone in 899 patients with high-risk diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma. At a median follow-up of 35.2 months, progression-free survival (PFS) was significantly improved with tafa-len-R-CHOP (HR 0.75; 95% CI 0.59-0.96; p=0.0194), yielding 2-year PFS rates of 71.1% versus 62.9%. Overall survival data are immature (HR 0.85 [0.63-1.14]), but there were fewer total deaths (82 vs 97) despite higher grade ≥3 adverse events (87% vs 76%) and treatment-related deaths (6% vs 4%) in the experimental arm. For clinicians treating high-risk DLBCL, this combination offers a meaningful PFS benefit but with increased toxicity, warranting careful patient selection and monitoring.
10.1016/S0140-6736(26)00866-4
Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This multicenter, single-arm, phase 1/2 trial evaluated single-fraction 19-Gy urethra-sparing SBRT for men with low- or intermediate-risk localized prostate cancer, aiming to determine its validity regarding biochemical disease control and safety. Key findings showed a 3-year biochemical relapse-free survival of 92.9% (95% CI, 85.4%-100%) among 43 treated patients, meeting the primary endpoint, with grade 2 GU and GI adverse events at 9.8% and 4.9% respectively at 3 years. This research directly addresses a novel, potentially more convenient treatment for cancer, offering a promising option for localized prostate cancer. The study implies that single-fraction SBRT is a valid and safe treatment, warranting further long-term assessment for disease control and clinical adoption.
10.1001/jamaoncol.2026.1886
Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This review provides an overview of antibody-drug conjugates (ADCs) in gynaecological malignancies, detailing key advances and future opportunities. It highlights three ADCs currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for HER2-expressing (3+ IHC) solid tumours, and tisotumab vedotin for cervical cancer. The abstract discusses current research priorities including novel targets, resistance mechanisms, sequencing strategies, toxicity management, and rational combinations, such as ADCs with immune checkpoint inhibitors. This offers clinicians a comprehensive update on ADC applications in gynaecological cancers, directly aligning with an interest in cancer-focused research and informing practical treatment considerations.
10.1038/s41571-026-01164-9
Management of Differentiated Thyroid Cancer.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This article presents a clinical framework for the risk-adapted management of differentiated thyroid cancer, emphasizing dynamic risk stratification from initial diagnosis through long-term follow-up. The methodology focuses on integrating clinicopathological staging with molecular risk characterization to develop and modify personalized treatment plans over time. Key findings highlight decision-making pathways for active surveillance in low-risk papillary cases, minimalist interventions for intermediate-risk patients, and systemic therapies for advanced disease. This framework provides clinicians with a structured approach to balance therapeutic benefits against risks while incorporating patient preferences into informed management recommendations.
10.1056/NEJMra2416814
Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This population-based study investigated cervical cancer mortality trends and estimated reductions in young women in England following HPV vaccination, utilizing mortality data from 2001-2024 and Poisson regression. Key findings show a 100% mortality reduction in women aged 20-24 years with high vaccination coverage (0 deaths vs. 23.1 expected). Overall, HPV vaccination was associated with a reduction of approximately 199.6 cervical cancer deaths (95% CI 125.0-274.2) by 2024, providing robust evidence for cancer prevention. These results strongly support global cervical cancer elimination goals and underscore the critical need for high vaccine uptake among young adolescents.
10.1016/S0140-6736(26)00918-9
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This Phase 3 randomized trial evaluated the efficacy of adding ivonescimab, a bispecific antibody targeting PD-1 and VEGF, to pemetrexed and carboplatin in 322 patients with EGFR-variant NSCLC following TKI progression. Ivonescimab significantly improved median overall survival to 16.8 months compared to 14.1 months with chemotherapy alone (HR 0.74; 95% CI, 0.58-0.95; P = .02). The treatment demonstrated a 2.7-month absolute survival benefit and a higher 30-month survival rate of 29.1% versus 18.4%, directly addressing the clinician’s interest in advanced oncological interventions. Despite a higher incidence of grade 3 or greater adverse events (67.1% vs 54.7%), this combination offers a clinically meaningful survival advantage for a high-need cancer population.
10.1001/jama.2026.7745
Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This multicohort, multicentre study developed and validated AI-assisted volumetric response criteria (ARTIMES) for pleural mesothelioma, addressing challenges with diameter-based methods. Using 10,926 CT scans from 2080 patients, ARTIMES demonstrated superior prognostic performance (concordance index 0.83 vs mRECIST 0.73, p=0.023) and detected progression a median of 5 weeks earlier (124 vs 162 days, p<0.0001). ARTIMES-based progression-free survival showed a stronger correlation with overall survival (R 88%) than mRECIST (R 6%). Pending prospective validation, ARTIMES could offer a more reliable response evaluation, improving clinical decision-making and trial efficiency in cancer care.
10.1016/S1470-2045(26)00084-7
Becotatug Vedotin for Recurrent/Metastatic Nasopharyngeal Carcinoma (Magic-M001): A Multicenter, Randomized Trial.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This multicenter, randomized trial investigated becotatug vedotin, an anti-EGFR antibody-drug conjugate, against chemotherapy in 173 patients with heavily pretreated recurrent/metastatic nasopharyngeal carcinoma. Becotatug vedotin significantly improved the objective response rate (30.2% vs 11.5%; P=0.003) and progression-free survival (median 5.82 vs 2.83 months; HR 0.63; P=0.01) compared to chemotherapy. Interim overall survival was encouraging at 17.08 vs 11.99 months, with comparable safety profiles between groups. These findings suggest becotatug vedotin offers a clinically meaningful new treatment option for patients with advanced NPC who have exhausted prior therapies, directly addressing a critical need in cancer management.
10.1016/j.annonc.2026.06.003
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This phase 3 trial (AENEAS2) evaluated aumolertinib with or without platinum-based chemotherapy as first-line treatment for advanced EGFR-mutated NSCLC. In 624 patients, median progression-free survival was significantly longer with combination therapy (28.9 months) versus monotherapy (18.9 months; HR 0.47, p<0.0001). This directly addresses the clinician’s interest in cancer research, specifically focused on improving outcomes in EGFR-mutant NSCLC. The regimen substantially delays progression but increases toxicity, requiring management per clinical practice; overall survival data are pending.
10.1016/S1470-2045(26)00090-2
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This scientific statement from the American Heart Association aims to standardize the definition, characterization, and adjudication of cardiovascular endpoints within oncology clinical trials. It proposes a framework linking drug-specific mechanisms to endpoint selection and standardizes definitions for adverse cardiovascular events, including heart failure, arrhythmias, myocarditis, and thrombotic events. This work is highly relevant to cancer research as it directly addresses the safety evaluation of cancer therapies, crucial for improving patient outcomes and supporting innovation in oncology. By harmonizing assessment, it will enhance risk stratification, facilitate regulatory acceptance, and inform clinical decision-making, ultimately improving patient safety in cancer treatment.
10.1200/JCO-25-01647
Jun 08 – Jun 15, 2026
Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This meta-analysis of 104 clinical trials involving 10,353 patients characterizes the treatment-related adverse events (TRAEs) associated with CD3-based T cell-engaging bispecific antibodies in cancer therapy. Results show high all-grade TRAE incidences of 97.5% for haematological malignancies and 97.9% for solid tumors, with grade 3 or worse events occurring in 70.3% and 45.3% of patients, respectively. Cytokine release syndrome was the most frequent all-grade event across both groups (~45%), while neutropenia and increased γ-glutamyltransferase were the leading severe toxicities depending on cancer type. These findings provide a critical safety benchmark for oncologists to optimize patient management and monitor for life-threatening complications like sepsis or respiratory failure.
10.1016/S1470-2045(26)00086-0
Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This international consensus study conducted a systematic review and meta-analysis of 6 studies (1,919 participants) evaluating MRI for prostate cancer screening, followed by a RAND/UCLA Appropriateness Method to develop PRISM recommendations. Key findings include a pooled biopsy recommendation rate of 19.2% (95% CI, 11.7-26.7), GG2+ cancer detection of 6.0% (95% CI, 3.1-9.0), and a positive predictive value for GG2+ cancer of 36.3% (95% CI, 21.1-51.4). The recommendations directly address cancer screening by standardizing MRI protocols for men aged 50-70 (or 45+ for Black men), emphasizing non-contrast abbreviated MRI, stage-gated reporting, and quality assurance. For clinicians focused on cancer research, this provides evidence-based guidance for implementing MRI in prostate cancer screening trials and programs.
10.1001/jamaoncol.2026.1711
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This international multicenter retrospective study evaluated the efficacy of high-dose methotrexate (HD-MTX) for CNS prophylaxis in 1,923 patients with ultra high-risk (UHR) large B-cell lymphoma. Results showed no significant difference in the 3-year CNS relapse rate between patients receiving HD-MTX (8.1%) and those who did not (9.3%), with an adjusted hazard ratio of 1.13. Even in landmark analyses of responding patients, isolated CNS relapse rates remained comparable (5.7% vs 5.9%), suggesting no prophylactic benefit across any UHR subgroup. These findings challenge current international guidelines and suggest that HD-MTX prophylaxis may be omitted in most UHR patients, potentially reducing treatment-related toxicity without increasing relapse risk.
10.1200/JCO-26-00947
Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This phase 1/2 nonrandomized clinical trial evaluated avelumab plus methotrexate as first-line therapy for low-risk gestational trophoblastic tumors (GTT). The regimen demonstrated acceptable safety, with only one dose-limiting toxicity and 22% of patients experiencing grade 2 or higher adverse events. A high rate of successful hCG normalization was achieved in 96.2% (90% CI, 85.9%-97.9%) of 26 assessable patients, with no relapses observed after a median 41-month follow-up. This combination represents a promising first-line strategy for low-risk GTT, potentially improving cure rates and preserving fertility, warranting further comparative studies.
10.1001/jamaoncol.2026.1697
Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This prospective quality improvement study evaluated the efficacy of prompt-directed ambient artificial intelligence (AI) for documenting multidisciplinary head and neck cancer tumor board discussions compared to manual methods. Results demonstrated that prompt-directed AI significantly improved total documentation scores (p=0.005) and tumor characteristic accuracy (q=0.042) compared to unprompted AI without increasing discussion time. Compared to manual documentation, ambient AI enhanced discussion domain scores (q<0.001) and total quality (p<0.001) while significantly reducing per-patient administrative burden (p<0.001). These findings suggest that integrating directed prompting into ambient AI workflows can optimize oncology documentation quality and clinical efficiency during complex multidisciplinary decision-making.
10.1016/j.annonc.2026.05.709
The future is not always uniform: rethinking radiotherapy through spatial fractionation.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This review examines the conceptual foundations and clinical applications of spatially fractionated radiotherapy (SFRT), an approach using intentional dose heterogeneity for large or complex tumors. The authors detail how SFRT techniques like GRID and lattice radiotherapy utilize high-dose peaks and low-dose valleys to achieve tumor regression while preserving the surrounding microenvironment. Clinical evidence suggests SFRT may offer acceptable toxicity profiles and immune modulation in cases where traditional uniform dose escalation is precluded by tissue tolerances. While promising for bulky malignancies, further research is required to standardize dosimetry and patient selection to ensure multicentre reproducibility in oncological practice.
10.1038/s41571-026-01161-y
Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.
CA-CANCER J CLIN · Q1 JOURNAL - RANK #1/326TOP-TIER
This review examines the evolving diagnostic and therapeutic landscape of systemic light-chain (AL) amyloidosis, a life-threatening plasma cell malignancy. It highlights how daratumumab-based frontline regimens have transformed standard care, alongside the integration of cytogenetic profiling and measurable residual disease assessment for risk-adapted management. The analysis covers emerging oncological interventions including BCL-2 inhibitors, bispecific antibodies, and CAR T-cell therapies targeting the underlying monoclonal plasma cell clone. These updates provide clinicians with practical diagnostic algorithms and evidence-based strategies to achieve durable organ recovery and improved survival outcomes.
10.3322/caac.70092
Electronic cigarette use after smoking cessation and lung cancer risk.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This large-scale cohort study of over 4.5 million Korean adults evaluated the association between post-cessation electronic cigarette use and lung cancer risk among former conventional smokers. Compared to complete quitters, e-cigarette users faced significantly higher risks of lung cancer incidence (aHR 1.56, 95% CI 1.24-1.97) and lung cancer-specific death (aHR 2.00, 95% CI 1.28-3.15). These associations remained consistent across both short-term and long-term quitters, with particularly pronounced risks observed in high-risk subgroups. The findings suggest that e-cigarette use may diminish the oncological benefits of smoking cessation, highlighting the clinical importance of promoting complete nicotine abstinence for lung cancer prevention.
10.1038/s41591-026-04469-5
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This target trial emulation used a nationwide database of over 113 million patients to evaluate the association between GLP-1 receptor agonist (GLP-1RA) use and the risk of 13 obesity-associated cancers (OACs) in obese, nondiabetic adults. Among 161,798 propensity-matched patients, GLP-1RA users demonstrated a significantly lower cumulative incidence of OACs compared to those receiving diet or exercise counseling (HR 0.59, 95% CI 0.53-0.67). These findings remained consistent across most subgroups, including BMI categories and specific medications like semaglutide, though the association was not significant for Black patients. The study suggests that GLP-1RAs may offer a potent pharmacological strategy for short-term cancer prevention in obese populations, though prospective trials are required to confirm these protective effects.
10.1016/j.annonc.2026.04.013
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This post-hoc analysis of two Phase 3 STAMPEDE trials evaluated a multimodal artificial intelligence (MMAI) model to predict abiraterone efficacy in 1,137 patients with non-metastatic, very high-risk prostate cancer. In the MMAI very high-risk group, adding abiraterone significantly improved 5-year metastasis-free survival from 62% to 81% (HR 0.47), whereas the standard high-risk group showed minimal benefit (82% vs 84%). These findings demonstrate that the MMAI biomarker effectively identifies patients most likely to benefit from treatment intensification while sparing others from unnecessary toxicity and costs. Clinicians can utilize this digital pathology-based tool to refine patient selection for abiraterone in localized, high-risk disease settings.
10.1016/j.annonc.2026.05.708
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This phase 1-2, open-label trial evaluated an all-oral decitabine-cedazuridine plus venetoclax regimen for newly diagnosed Acute Myeloid Leukemia (AML) patients aged ≥75 or ineligible for intensive chemotherapy. No drug-drug interactions were observed. In phase 2b, 47% of patients achieved a complete response (CR), and 63% achieved CR or CR with incomplete hematologic recovery (CRi), with a median overall survival of 15.5 months. This all-oral regimen offers a less burdensome, viable treatment alternative for a vulnerable cancer patient population, directly addressing a critical need in AML management and potentially improving accessibility and quality of life.
10.1056/NEJMoa2510223